The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tresulfan     1,4- bis(methylsulfonyloxy)butane- 2,3-diol

Synonyms: Treosulfan, NSC-39068, NSC-260698, NSC39068, NSC39069, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Treosulphan


Psychiatry related information on Treosulphan


High impact information on Treosulphan


Chemical compound and disease context of Treosulphan


Biological context of Treosulphan

  • Furthermore, long-term preincubation with bryostatin-1 or TPA, both of which are known to down-regulate PKC protein levels, likewise inhibited treosulfan-induced apoptosis [8].
  • DNA alkylation and interstrand cross-linking by treosulfan [13].
  • Bcl-2 provided only moderate protection from synergistic induction of glioma cell death by treosulfan and BSO [14].
  • In the present study, we report that permanent donor-specific tolerance and stable mixed multilineage chimerism can successfully be achieved across haploidentical MHC barriers when Treosulfan is administered in combination with anti-T-cell mAb and T-cell-depleted donor bone marrow cells [15].
  • Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors [16].

Anatomical context of Treosulphan


Associations of Treosulphan with other chemical compounds


Gene context of Treosulphan


Analytical, diagnostic and therapeutic context of Treosulphan


  1. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Pedersen-Bjergaard, J., Ersbøll, J., Sørensen, H.M., Keiding, N., Larsen, S.O., Philip, P., Larsen, M.S., Schultz, H., Nissen, N.I. Ann. Intern. Med. (1985) [Pubmed]
  2. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Schmidmaier, R., Baumann, P., Simsek, M., Dayyani, F., Emmerich, B., Meinhardt, G. Blood (2004) [Pubmed]
  3. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Scheulen, M.E., Hilger, R.A., Oberhoff, C., Casper, J., Freund, M., Josten, K.M., Bornhäuser, M., Ehninger, G., Berdel, W.E., Baumgart, J., Harstrick, A., Bojko, P., Wolf, H.H., Schindler, A.E., Seeber, S. Clin. Cancer Res. (2000) [Pubmed]
  4. Myeloablative and immunosuppressive properties of treosulfan in mice. Sjöö, F., Hassan, Z., Abedi-Valugerdi, M., Griskevicius, L., Nilsson, C., Remberger, M., Aschan, J., Concha, H., Gaughan, U., Hassan, M. Exp. Hematol. (2006) [Pubmed]
  5. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Corrie, P.G., Shaw, J., Spanswick, V.J., Sehmbi, R., Jonson, A., Mayer, A., Bulusu, R., Hartley, J.A., Cree, I.A. Br. J. Cancer (2005) [Pubmed]
  6. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Topaly, J., Fruehauf, S., Ho, A.D., Zeller, W.J. Br. J. Cancer (2002) [Pubmed]
  7. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Andersson, G., Illigens, B.M., Johnson, K.W., Calderhead, D., LeGuern, C., Benichou, G., White-Scharf, M.E., Down, J.D. Blood (2003) [Pubmed]
  8. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Schmidmaier, R., Oellerich, M., Baumgart, J., Emmerich, B., Meinhardt, G. Exp. Hematol. (2004) [Pubmed]
  9. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Fichtner, I., Becker, M., Baumgart, J. Eur. J. Cancer (2003) [Pubmed]
  10. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Neale, M.H., Myatt, N., Cree, I.A., Kurbacher, C.M., Foss, A.J., Hungerford, J.L., Plowman, P.N. Br. J. Cancer (1999) [Pubmed]
  11. Antitumor activity of treosulfan against human breast carcinomas. Köpf-Maier, P., Sass, G. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  12. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Schmidt-Hieber, M., Blau, I.W., Trenschel, R., Andreesen, R., Stuhler, G., Einsele, H., Kanz, L., Keilholz, U., Marinets, O., Beelen, D.W., Fauser, A.A., Volin, L., Ruutu, T., Uharek, L., Fietz, T., Knauf, W., Hopfenmüller, W., Thiel, E., Freund, M., Casper, J. Bone Marrow Transplant. (2007) [Pubmed]
  13. DNA alkylation and interstrand cross-linking by treosulfan. Hartley, J.A., O'Hare, C.C., Baumgart, J. Br. J. Cancer (1999) [Pubmed]
  14. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. Reber, U., Wüllner, U., Trepel, M., Baumgart, J., Seyfried, J., Klockgether, T., Dichgans, J., Weller, M. Biochem. Pharmacol. (1998) [Pubmed]
  15. Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. van Pel, M., van Breugel, D.W., Vos, W., Ploemacher, R.E., Boog, C.J. Bone Marrow Transplant. (2004) [Pubmed]
  16. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Hilger, R.A., Harstrick, A., Eberhardt, W., Oberhoff, C., Skorzec, M., Baumgart, J., Seeber, S., Scheulen, M.E. Cancer Chemother. Pharmacol. (1998) [Pubmed]
  17. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Weissert, R., Wiendl, H., Pfrommer, H., Storch, M.K., Schreiner, B., Barth, S., Seifert, T., Melms, A., Dichgans, J., Weller, M. J. Neuroimmunol. (2003) [Pubmed]
  18. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Beelen, D.W., Trenschel, R., Casper, J., Freund, M., Hilger, R.A., Scheulen, M.E., Basara, N., Fauser, A.A., Hertenstein, B., Mylius, H.A., Baumgart, J., Pichlmeier, U., Hahn, J.R., Holler, E. Bone Marrow Transplant. (2005) [Pubmed]
  19. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Kröger, N., Shimoni, A., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Wolschke, C., Renges, H., Dahlke, J., Atanackovic, D., Nagler, A., Zander, A. Bone Marrow Transplant. (2006) [Pubmed]
  20. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Spieth, K., Kaufmann, R., Gille, J. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  21. Comparison of single-, double- or triple-exposure protocols for the rodent bone marrow/peripheral blood micronucleus assay using 4-aminobiphenyl and treosulphan. Gulati, D.K., Wojciechowski, J.P., Kaur, P. Mutat. Res. (1990) [Pubmed]
  22. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Meden, H., Wittkop, Y., Kuhn, W. Anticancer Res. (1997) [Pubmed]
  23. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. Wick, W., Stock, J., Seyfried, J., Baumgart, J., Wüllner, U., Weller, M. Int. J. Oncol. (2002) [Pubmed]
  24. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bojko, P., Hilger, R.A., Ruehm, S.G., Dirsch, O., Seeber, S., Scheulen, M.E. Bone Marrow Transplant. (2003) [Pubmed]
  25. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Hilger, R.A., Jacek, G., Oberhoff, C., Kredtke, S., Baumgart, J., Seeber, S., Scheulen, M.E. Cancer Chemother. Pharmacol. (2000) [Pubmed]
  26. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Meinhardt, G., Dayyani, F., Jahrsdörfer, B., Baumgart, J., Emmerich, B., Schmidmaier, R. Br. J. Haematol. (2003) [Pubmed]
WikiGenes - Universities